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Sir,
Werneke et al (2004) highlighted several important issues in
their article. They confirmed the findings of other authors (Ernst
and Cassileth, 1998; Newell and Sanson-Fisher, 2000) that herbal
supplements are commonly used among cancer patients, but often
unsupervised. Health care professionals have expressed concerns
about their safety and possible interaction with pharmaceutical
drugs. The authors suggested a joint medicines information and
toxicology service to address such concerns. Such a service already
exists.
The Medical Toxicology Unit, Guy’s & St Thomas’ Hospital
Trust, has been providing information on herbal medicines to
health care professionals for over 10 years. As well as providing
safety information, we also assist in reviewing the suspected
adverse health effects of these medicines. This work led to the
development of the Chinese Medicine Advisory Service in 2001,
which specialises in providing information to health care
professionals on issues surrounding the use of Chinese herbal
medicines by their patients. We would like to add some of our
findings and experience to those published in the article.
A herb is deemed potentially toxic either because it contains
pharmacologically active constituents, or if the plant extract has
been shown to be toxic in animal studies or if there have been
previous case reports of toxicity associated with its use. Among
these three sources we feel that, generally, high-quality clinical case
reports are the most informative. We scrutinise each report to
establish its causal relationship and the circumstances of poison-
ing, considering factors such as whether the toxicity was dose
related or due to inappropriate use. From our work, we have found
that most adverse effects arise from human errors such as
overdosage or poor quality control.
For any enquiry, we try to take into account the potential
benefits of the ingredients. We investigate such claims with
bibliographical evidence. Practising herbalists also inform us of
their empirical experience. We arrive at a pragmatic decision and
our advice is based on the balance between risks and benefits of
the ingredients.
Potential herb–drug interactions is an area where it can be more
difficult to give balanced answers at present. This is because most
of the suspicions are extrapolated from what is known about the
pharmacology of the herb or its constituents, and not from actual
clinical events. This is also a major problem with drug–drug
interactions, as was clearly expressed by Stockley (2002), ‘The data
on interactions are of widely varying quality and reliability.
Sometimes they are no more than speculative and theoretical
scaremongering guesswork, hallowed by repeated quotation until
they become virtually set in stone’. This is not to suggest that
potential herb–drug interactions should be ignored, rather it
illustrates the need for further investigations to be able to identify
combinations in which interactions are likely to result in
significant adverse effects. The significance of drug–herb interac-
tion in cancer treatment can only be properly evaluated by a
prospective study of patients taking herbal medicine in addition to
conventional therapy and evaluating the benefits and adverse
effects due to their interaction. Having carried out this initial
survey of patients, Dr Werneke and the team are well placed to be
able to carry out such a prospective study of their patients, and
show the clinical relevance of the suspected interactions.
Until further data are available, our current practice in making
recommendation with regard to possible herb–drug interactions is
to suggest closer monitoring of the patient, and we advise the
physician on the area that needs to be focused. For instance, in a
patient who takes warfarin, we would normally recommend more
frequent measurement of the INR for a period of time after the
introduction of a new herbal agent.
There is some evidence suggesting that the supplementary use of
herbal medicines can have additional beneficial effects. An in vitro
study has shown that gamolenic acid (oil from the seeds of evening
primrose and borage) potentiates the cytotoxicity of paclitaxel and
vinorelbime in human breast cancer cell lines (Menendez et al,
2002). There are a number of clinical trials from China that
suggested that Chinese herbal medicines used together with
conventional therapies improve the mortality and morbidity of
cancer patients (Liu et al, 2001; Liang et al, 2003). These findings
were often substantiated by experimental studies (Liu et al, 2002;
Qu et al, 2003). These trials will need to be confirmed
independently, but nevertheless suggest interesting synergism.
Currently, the amount of evidence based on local data is limited.
Between 1999 and 2002, the CSM/MHRA received 345 herbal
adverse reaction reports; of these 40% related to St John’s Wort
(Barnes, 2003). Improved awareness of and reporting suspected
herbal adverse effects and interactions are clearly required.
Doctors should take a full drug history from their patients,
including traditional medicines and herbal products. The World
Health Organisation has emphasised the importance of exchanging
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www.bjcancer.comknowledge through an international network to overcome shortage
of information from own region (WHO Traditional Medicine
Strategy, 2002–2005, 2002). We believe that multiple reference
sources, especially those published from countries where herbal
medicine is more commonly used, should be used in order to
provide an evidence-based advice.
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Sir,
Drug information services such as the Chinese Medicine
Advisory Service at the Medical Toxicology Unit at Guy’s and St
Thomas’ Hospital Trust make an important contribution to the
safety management of patients taking complementary alternative
medicines (CAMs). We are aware that these services exist and
increased resort to the service they offer is needed. Our proposal is
that doctors will need to devote time to discussing CAM use in
outpatient clinics although the complexities of side effects and
interactions may require clinics which are run jointly with a local
medicines information and toxicology services (Werneke et al,
2004). Such work may not be feasible in routine outpatient clinics
where patients may be seen only briefly. Joint clinics would not
only address drug safety concerns but also the patients’ motivation
for opting for CAMs, for instance to gain a greater degree of
control over their illness and its treatment, and thereby to regain
control over their lives (Sparber et al, 2000).
We agree with Shia et al that herbal remedies may have
beneficial synergistic effects with conventional therapies. How-
ever, patients may take CAMs for a variety of reasons
including reduction of cytotoxicity and its associated side
effects rather than increasing it. This is highlighted by an e-
mail we received in response to out study from a naturopath
who asserted:’ yyou will find that more people die of the
chemotherapy than the cancer itself. Therefore if the herbs are
making the chemo less effective this could be a beneficial
thingy’. Thus, there is a need to work out and implement an
individualised treatment plan for each patient wishing to use
CAMs, and this may be beyond the scope of a drug
information service.
Shia et al suggest prospective studies to evaluate the
interactions between conventional and complementary medicines.
However, such studies may be difficult to conduct if there are
reasons to suspect potentially serious interactions or a significant
reduction in efficacy of the conventional treatment, which could
lead to a reduction in survival time. It may not be ethically
acceptable to opt for ‘watchful waiting’ in such cases, and one
may wish to err on the side of caution. In view of this, we
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